Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12002541 | 0.95 | HDAC4 (0.51) | KMT2AMEN1TDP1HDAC4HDAC6 | |
| SCHEMBL13226836 | 0.84 | HDAC4 (0.49) | TDP1HDAC4HDAC6SIGMAR1SMN1; SMN2 | |
| SCHEMBL8371453 | 0.84 | HDAC4 (0.49) | TDP1HDAC4HDAC6LTB4RLTB4R2 | |
| SCHEMBL8064820 | 0.84 | HDAC4 (0.49) | KMT2AMEN1TDP1HDAC4HDAC6 | |
| SCHEMBL2255946 | 0.83 | KMT2A (0.49) | KMT2AMEN1TDP1L3MBTL1KDM4E | |
| SCHEMBL13536796 | 0.82 | HDAC4 (0.48) | TDP1HDAC4HDAC6SIGMAR1LMNA | |
| SCHEMBL1399311 | 0.82 | TDP1 (0.56) | KMT2AMEN1TDP1HDAC4HDAC6 | |
| SCHEMBL1707082 | 0.82 | RAB9A (0.51) | HDAC4HDAC6L3MBTL1SIGMAR1ALDH1A1 | |
| SCHEMBL1708481 | 0.82 | HTT (0.56) | HDAC4HDAC6KDM4ESIGMAR1SMN1; SMN2 | |
| SCHEMBL1515938 | 0.82 | HDAC6 (0.48) | KMT2ATDP1HDAC4HDAC6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-20240284786-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT, COMPOUND, AND ELECTRONIC EQUIPMENT | IDEMITSU KOSAN CO.,LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-09 | — | — | US | disclosed |
| CN-113825748-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3911643-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-1971582-B1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1971582-B1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1981877-B1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-7750155-B2 | Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| WO-2007076431-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060083676-A1 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTIA N.V. (BE) | 2006-04-20 | — | — | US | disclosed |
| EP-1492571-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082350-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-09 | — | — | WO | disclosed |
| EP-0640080-B1 | SUBSTITUTED INDOLES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX INC (US) | 1997-10-22 | — | — | EP | disclosed |
| EP-0640080-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS. | SYNTEX INC (US) | 1995-03-01 | — | — | EP | disclosed |
| US-5380739-A | Angiotensin II antagonists | SYNTEX (U.S.A.) INC. (US) | 1995-01-10 | — | — | US | disclosed |
| WO-1993023391-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993014086-A1 | SUBSTITUTED 1-ISOQUINOLONE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5212195-A | Substituted indole antagonists derivatives which are angiotensin II | SYNTEX (U.S.A.) INC. (US) | 1993-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | KMT2A 1994/4885MEN1 4864/4885TDP1 3903/4885 |
| US-20060083676-A1 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | GRM3, GRM1, GRM2 | KMT2A 2490/4885MEN1 2520/4885TDP1 4644/4885 |
| US-20240284786-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT, COMPOUND, AND ELECTRONIC EQUIPMENT | EML4, OR10J3, L1CAM | KMT2A 1471/4885MEN1 750/4885TDP1 2156/4885 |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | KMT2A 4067/4885MEN1 4216/4885TDP1 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.